These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18269339)

  • 1. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
    Gupta S; Singh RK; Dastidar S; Ray A
    Expert Opin Ther Targets; 2008 Mar; 12(3):291-9. PubMed ID: 18269339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in cathepsin S inhibitor design.
    Link JO; Zipfel S
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin S inhibitors as novel immunomodulators.
    Thurmond RL; Sun S; Karlsson L; Edwards JP
    Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a potent and selective noncovalent cathepsin S inhibitor.
    Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
    Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
    Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
    Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
    Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
    Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
    Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins.
    Reich M; van Swieten PF; Sommandas V; Kraus M; Fischer R; Weber E; Kalbacher H; Overkleeft HS; Driessen C
    J Leukoc Biol; 2007 Apr; 81(4):990-1001. PubMed ID: 17261546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine cathepsin proteases as pharmacological targets in cancer.
    Palermo C; Joyce JA
    Trends Pharmacol Sci; 2008 Jan; 29(1):22-8. PubMed ID: 18037508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical properties and regulation of cathepsin K activity.
    Lecaille F; Brömme D; Lalmanach G
    Biochimie; 2008 Feb; 90(2):208-26. PubMed ID: 17935853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteine protease cathepsin S as a key step in antigen presentation.
    Liu W; Spero DM
    Drug News Perspect; 2004; 17(6):357-63. PubMed ID: 15334187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery strategies for cathepsin inhibitors in joint diseases.
    Wang D; Brömme D
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1015-28. PubMed ID: 16296806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal cysteine proteases: structure, function and inhibition of cathepsins.
    Roberts R
    Drug News Perspect; 2005 Dec; 18(10):605-14. PubMed ID: 16491162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
    Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
    Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunodiagnostic/protective role of cathepsin L cysteine proteinases secreted by Fasciola species.
    Dixit AK; Dixit P; Sharma RL
    Vet Parasitol; 2008 Jul; 154(3-4):177-84. PubMed ID: 18486345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine cathepsins: cellular roadmap to different functions.
    Brix K; Dunkhorst A; Mayer K; Jordans S
    Biochimie; 2008 Feb; 90(2):194-207. PubMed ID: 17825974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Future of Cysteine Cathepsins in Disease Management.
    Kramer L; Turk D; Turk B
    Trends Pharmacol Sci; 2017 Oct; 38(10):873-898. PubMed ID: 28668224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.